GNAO1 mutated in pediatric encephalopathies encodes the major neuronal G protein Gαo. Of the more than 80 pathogenic mutations, most are single amino acid substitutions spreading across the Gαo sequence. We performed extensive characterization of Gαo mutants, showing abnormal GTP uptake and hydrolysis and deficiencies in binding Gβγ and RGS19. Plasma membrane localization of Gαo was decreased for a subset of mutations that leads to epilepsy; dominant interactions with GPCRs also emerged for the more severe mutants. Pathogenic mutants massively gained interaction with Ric8A and, surprisingly, Ric8B proteins, relocalizing them from cytoplasm to Golgi. Of these 2 mandatory Gα-subunit chaperones, Ric8A is normally responsible for the Gαi/Gαo, Gαq, and Gα12/Gα13 subfamilies, and Ric8B solely responsible for Gαs/Gαolf. Ric8 mediates the disease dominance when engaging in neomorphic interactions with pathogenic Gαo through imbalance of the neuronal G protein signaling networks. As the strength of Gαo-Ric8B interactions correlates with disease severity, our study further identifies an efficient biomarker and predictor for clinical manifestations in GNAO1 encephalopathies. Our work uncovers the neomorphic molecular mechanism of mutations underlying pediatric encephalopathies and offers insights into other maladies caused by G protein malfunctioning and further genetic diseases.
Gonzalo P. Solis, Alexey Koval, Jana Valnohova, Arghavan Kazemzadeh, Mikhail Savitsky, Vladimir L. Katanaev
Title and authors | Publication | Year |
---|---|---|
A Personalized 14-3-3 Disease-Targeting Workflow Yields Repositioning Drug Candidates
Larasati YA, Solis GP, Koval A, Korff C, Katanaev VL |
Cells | 2025 |
Novel Mutation at Cys225 in GNAO1‐Associated Developmental and Epileptic Encephalopathies: Clinical, Molecular, and Pharmacological Profiling of Case Studies
Larasati YA, Solis GP, Koval A, François\u2010Heude M, Piarroux J, Roubertie A, Yang R, Zhang Y, Cao D, Korff CM, Katanaev VL |
MedComm | 2025 |
Personalized allele-specific antisense oligonucleotides for GNAO1-neurodevelopmental disorder
Shomer I, Mor N, Raviv S, Budick-Harmelin N, Matchevich T, Avkin-Nachum S, Rais Y, Haffner-Krausz R, Haimovich A, Ziv A, Fluss R, Ben-Ze\u2019ev B, Heimer G, Silachev DN, Katanaev VL, Dominissini D |
Molecular Therapy. Nucleic Acids | 2024 |
Clinical Cases and the Molecular Profiling of a Novel Childhood Encephalopathy-Causing GNAO1 Mutation P170R
Larasati YA, Solis GP, Koval A, Griffiths ST, Berentsen R, Aukrust I, Lesca G, Chatron N, Ville D, Korff CM, Katanaev VL |
Cells | 2023 |